Avacta Group plc
("Avacta" or "the Company")
Change of Adviser
Avacta Group plc (Stock Code: AVCT.L), an AIM listed company which provides
novel detection and analysis technology for the pharmaceutical, defence/
security and clinical diagnostics markets, announces that it has appointed
Daniel Stewart & Company plc as the Company's Nominated Adviser and Joint
Broker with immediate effect. Novum Securities Limited continues to act as
Joint Broker.
13 October 2008
Enquiries:
Avacta Group plc Tel: 0870 835 4367
Alastair Smith, Chief Executive Officer
Tim Sykes, Chief Financial Officer
www.avacta.com
Daniel Stewart & Company plc Tel: 020 7776 6550
Lindsay Mair/Tessa Smith
www.danielstewart.co.uk
Novum Securities Limited Tel: 020 7562 4700
Henry Turcan/Michael Brennan
Haggie Financial LLP Tel: 020 7417 8989
Nicholas Nelson/Kathy Boate Nicholas.nelson@haggie.co.uk
Notes to Editors:
About Avacta
Avacta was spun-out from the University of Leeds in 2004 by its current
management team as a biophysics company, with the aim of combining the
disciplines of physics and biology to develop innovative technologies and
expert technical services to address needs in the pharmaceutical, defence and
clinical diagnostics markets. Avacta has a core bio-analytical technology
development programme addressing the needs of the biopharmaceutical sector to
fully characterise their new products at the earliest stage in their
development to reduce the risk of late stage failure. High value solutions in
defence and clinical diagnostics are also being provided by these core
bio-analytical technologies. A successful and growing part of the Avacta
business model is its technical services arm, Avacta Analytical Ltd, which is
focused on providing leading edge contract research to the biopharmaceutical
and healthcare/personal-care materials sectors. Avacta listed on AIM in August
2006 through the reverse takeover of Readybuy plc which changed its name to
Avacta Group plc.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.